Vaccinating immunocompetent individ

Vaccinating immunocompetent individuals aged ≥65 years with PCV13 is efficacious. However the absolute incidence of vaccine-type disease will likely become very low due to wider benefits of the childhood PCV13 vaccination programme, such that a specific PCV13 vaccination programme targeting the immunocompetent elderly would not be cost-effective

Vaccinating immunocompetent individuals aged ≥65 years with PCV13 is efficacious. However the absolute incidence of vaccine-type disease will likely become very low due to wider benefits of the childhood PCV13 vaccination programme, such that a specific PCV13 vaccination programme targeting the immunocompetent elderly would not be cost-effective.

Vaccinating immunocompetent individuals aged > = 65 years with PCV13 is efficacious. However the absolute incidence of vaccine-type. Disease will likely become very low due to wider benefits of the childhood PCV13, vaccination programme such that a specific. PCV13 vaccination programme targeting the immunocompetent elderly would not be cost-effective.